Overview: Thyroglobulin Immunohistochemistry TestIntroduction: The Thyroglobulin Immunohistochemistry Test detects thyroglobulin to diagnose thyroid cancer, causing neck swelling or pain. Aligned with 2023 ATA guidelines, it uses immunohistochemistry for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected thyroid cancer.
Other Names: Thyroglobulin IHC Assay, Thyroid Cancer IHC Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: Thyroglobulin testing began in the 1980s with thyroid cancer research. Immunohistochemistry-based methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects thyroglobulin to diagnose thyroid cancer, guides treatment, and evaluates patients with neck swelling or pain.
Test Parameters: 1. Thyroglobulin Protein
Pretest Condition: No fasting required. Collect tissue via thyroid biopsy or surgery. Report history of neck swelling, pain, or thyroid nodules.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document neck swelling, pain, hoarseness, or family history of thyroid cancer. Include current medications, especially thyroid hormone therapy.
Consent: Written consent required, detailing the tests purpose, cancer implications, and risks of biopsy or surgery.
Procedural Considerations: Uses immunohistochemistry to detect thyroglobulin in thyroid tissue. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for thyroid cancer diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce staining accuracy.
Clinical Significance: Positive thyroglobulin staining confirms thyroid cancer (e.g., papillary or follicular), guiding surgery or radioiodine therapy. Negative staining may require further marker testing.
Specialist Consultation: Consult an endocrinologist or oncologist for result interpretation and treatment planning.
Additional Supporting Tests: TTF-1 IHC, serum thyroglobulin, or thyroid ultrasound to confirm thyroid cancer diagnosis.
Test Limitations: Not specific to one thyroid cancer type; benign thyroid conditions may express thyroglobulin. Clinical correlation is needed.
References: ATA Thyroid Cancer Guidelines, 2023; American Journal of Surgical Pathology, Baloch ZW, 2022.
